| Pharmaceutical Information |
| Drug Name |
Etonogestrel |
| Drug ID |
BADD_D00852 |
| Description |
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692] |
| Indications and Usage |
Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990]
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698] |
| Marketing Status |
approved; investigational |
| ATC Code |
G03AC08 |
| DrugBank ID |
DB00294
|
| KEGG ID |
D04104
|
| MeSH ID |
C044815
|
| PubChem ID |
6917715
|
| TTD Drug ID |
D02KIU
|
| NDC Product Code |
64918-1500; 78206-145; 71161-147; 63190-0260; 45541-1192; 60870-0475; 63190-0480; 64918-1906; 65089-0053 |
| UNII |
304GTH6RNH
|
| Synonyms |
etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon |
|
| Chemical Information |
| Molecular Formula |
C22H28O2 |
| CAS Registry Number |
54048-10-1 |
| SMILES |
CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Vulvovaginal inflammation | 21.14.02.014 | 0.001199% | | - |
|
|
|
